ArticleBMC musculoskeletal disorders2025
Comparison of short-term effectiveness between unilateral biportal endoscopic and MED-assisted transforaminal lumbar interbody fusion for mild single-segment lumbar spondylolisthesis.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Unilateral biportal endoscopic transforaminal lumbar interbody fusion versus minimally invasive transforaminal lumbar interbody fusion for single-level lumbar spondylolisthesis: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Unilateral biportal endoscopic lumbar interbody fusion: Radiographic and clinical outcomes in grade I lumbar spondylolisthesis.Medicine · 2026Article
- Article
- A Comparative Study of the No-Punch Technique in Reducing Surgical Complications Associated with Unilateral Biportal Endoscopic Spine Surgery.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe purpose of this study was to compare the short-term clinical efficacy of unilateral biportal endoscopic transforaminal lumbar interbody fusion (UBE-TLIF) versus minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) with microendoscopic discectomy (MED) for lumbar spondylolisthesis.
methodsThe patients were divided into MIS-TLIF group and UBE-TLIF group according to the surgical procedures. The two groups were compared in terms of surgery-related parameters, postoperative functional scores and complications.
resultsCompared with the MIS-TLIF group, the UBE-TLIF group had a longer surgical time, less intraoperative and postoperative blood loss, and less length of stay (LOS) (p < 0.001). Comparison of visual analog scale (VAS) scores and Oswestry Disability Index (ODI) scores at each postoperative time point between the two groups showed no statistically significant difference (p > 0.05). At the final follow-up, the lumbar lordosis (LL) and Cobb angle were improved in both groups compared with the preoperative period, but the difference between the pre- and postoperative of the two groups was not statistically significant (p > 0.05). The intervertebral fusion of the two groups was compared at each postoperative time point, and the difference was not statistically significant (p > 0.05). During the follow-up period, there was no statistically significant difference between the two groups in terms of complication rate (p > 0.05).
conclusionIn the treatment of mild lumbar spondylolisthesis, UBE-TLIF can achieve satisfactory short-term results comparable to MED-assisted MIS-TLIF. Compared with MED-assisted MIS-TLIF, UBE-TLIF has the advantages of less perioperative bleeding, shorter LOS, and faster early postoperative recovery, despite the longer surgical time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.